Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immuneering Corporation stock logo
IMRX
Immuneering
$2.77
+52.2%
$1.56
$1.00
$3.83
$65.49M0.012.50 million shs13.62 million shs
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
$5.26
-2.8%
$4.98
$3.13
$26.05
$81.27M2.72302,869 shs172,163 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.44
+0.6%
$3.15
$2.57
$6.88
$21.13M0.639,025 shs3,426 shs
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.31
$1.44
$1.10
$16.10
$80.42M1.351.12 million shs648,666 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immuneering Corporation stock logo
IMRX
Immuneering
-23.21%-16.13%+26.39%+8.33%+18.57%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-3.91%-6.24%+9.74%+4.24%-77.75%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-1.16%-0.87%+5.23%-7.57%-47.14%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-3.68%-14.94%-5.07%-19.14%-88.30%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Immuneering Corporation stock logo
IMRX
Immuneering
3.303 of 5 stars
3.32.00.00.02.95.00.6
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2.2804 of 5 stars
3.52.00.00.03.11.70.0
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.6154 of 5 stars
0.03.00.00.01.01.70.6
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
4.2434 of 5 stars
3.04.00.04.72.81.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Immuneering Corporation stock logo
IMRX
Immuneering
2.60
Moderate Buy$13.25378.34% Upside
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
3.00
Buy$62.221,082.93% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
2.00
Hold$13.31916.22% Upside

Current Analyst Ratings Breakdown

Latest NAII, IMRX, JSPR, and PLRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/5/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
5/15/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$80.00 ➝ $65.00
5/13/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $33.00
5/7/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.00
5/6/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
4/10/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
3/24/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
3/21/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Immuneering Corporation stock logo
IMRX
Immuneering
$320K311.54N/AN/A$1.33 per share2.08
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/A$4.11 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$1.58M50.90N/AN/A$5.00 per share0.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Immuneering Corporation stock logo
IMRX
Immuneering
-$61.04M-$1.96N/AN/AN/AN/A-119.22%-99.22%8/5/2025 (Estimated)
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$71.27M-$5.24N/AN/AN/AN/A-109.45%-89.82%8/12/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
-$210.30M-$3.61N/AN/AN/AN/A-67.56%-52.54%8/6/2025 (Estimated)

Latest NAII, IMRX, JSPR, and PLRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/12/2025Q1 2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$1.17-$1.41-$0.24-$1.41N/AN/A
5/5/2025Q1 2025
Immuneering Corporation stock logo
IMRX
Immuneering
-$0.41-$0.42-$0.01-$0.42N/AN/A
3/20/2025Q4 2024
Immuneering Corporation stock logo
IMRX
Immuneering
-$0.42-$0.58-$0.16-$0.58N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Immuneering Corporation stock logo
IMRX
Immuneering
N/AN/AN/AN/AN/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Immuneering Corporation stock logo
IMRX
Immuneering
N/A
7.48
7.48
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/A
4.31
4.31
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
N/A
11.03
11.03

Institutional Ownership

CompanyInstitutional Ownership
Immuneering Corporation stock logo
IMRX
Immuneering
67.65%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
79.85%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
97.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Immuneering Corporation stock logo
IMRX
Immuneering
6035.99 million27.75 millionNot Optionable
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2015.02 million14.33 millionOptionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
9061.39 million56.48 millionOptionable

Recent News About These Companies

Analysts Issue Forecasts for PLRX FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Immuneering stock logo

Immuneering NASDAQ:IMRX

$2.77 +0.95 (+52.20%)
Closing price 04:00 PM Eastern
Extended Trading
$2.55 -0.22 (-7.94%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Jasper Therapeutics stock logo

Jasper Therapeutics NASDAQ:JSPR

$5.26 -0.15 (-2.77%)
Closing price 04:00 PM Eastern
Extended Trading
$5.26 0.00 (-0.10%)
As of 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.44 +0.02 (+0.56%)
Closing price 03:58 PM Eastern
Extended Trading
$3.47 +0.03 (+0.87%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Pliant Therapeutics stock logo

Pliant Therapeutics NASDAQ:PLRX

$1.31 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.36 +0.05 (+3.74%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.